TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Symptom Based Treatment of Neuropathic Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* aged than 20 years~* Neuropathic pain symptoms : LANSS (Leeds assessment of neuropathic symptoms and signs) score of 12 and above~* Visual analogue scale score of 3 and above~Exclusion Criteria:~* No pregnancy~* systemic disease~* psychiatric disease

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregabalin and Oxcarbazpepine (Type: EXPERIMENTAL): Pregabalin and Oxcarbazepine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Trial to Determine the Effective N-acetylcysteine Dose for Opioid Reduction for Spine Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing elective spine surgery involving 4 levels or less of the thoracic, lumbar, or sacral spine.~* 18 years of age and older.~Exclusion Criteria:~* Less than 40kg in weight.~* Unable to provide written, informed consent.~* History of an adverse or anaphylactoid reaction to acetylcysteine.~* Active asthma, wheezing, or using inhaled bronchodilators.~* Pregnant Women~* Known blood clotting deficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Dose Response Curve Placebo (Type: PLACEBO_COMPARATOR): 5 participants will be randomized to the placebo group to estimate the dose response curve and to identify the optimal dose.
- Dose Response Curve N-acetylcysteine 50 mg/kg (Type: ACTIVE_COMPARATOR): 5 participants will be randomized to the N-acetylcysteine 50 mg/kg group to estimate the dose response curve and to identify the optimal dose.
- Dose Response Curve N-acetylcysteine 100 mg/kg (Type: ACTIVE_COMPARATOR): 5 participants will be randomized to the N-acetylcysteine 100 mg/kg group to estimate the dose response curve and to identify the optimal dose.
- Dose Response Curve N-acetylcysteine 150 mg/kg (Type: ACTIVE_COMPARATOR): 5 participants will be randomized to the N-acetylcysteine 150 mg/kg group to estimate the dose response curve and to identify the optimal dose.
- Opioid Reduction with Optimal N-acetylcysteine Dose (Type: ACTIVE_COMPARATOR): Once the optimal N-acetylcysteine dose is identified, 15 additional participants will be randomized to the optimal dose to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose. Primary and secondary outcomes will only be evaluated for the placebo group and optimal NAC group.
- Placebo (Type: PLACEBO_COMPARATOR): 15 Participants will be randomized to placebo to estimate the difference in opioid consumption between patients on placebo vs. the optimal dose. Primary and secondary outcomes will only be evaluated for the placebo group and optimal NAC group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Polyphenols and Insulin Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Absence of anti HIV or anti hepatitis C antibodies and of HBS antigen.~* Acceptable biological assessment of the hepatic and renal functions (γGT, ALAT, ASAT \< 3 times the normal value and serum creatinine \<150 micromol/l).~* Age between 30 and 55 years.~* Fasting plasma glucose \<110 mg/dl and absence of any anti-diabetic treatment~* No regular physical activity (Voorips index \< 9)~* Absence of any drug treatment in progress and during the last 2 months~* Subjects with at least one 1st degree relative with T2D and with a body mass index between 25 and 35 kg/m² and a waist measurement \>94 cm for males, and \>80 cm for females.~* Normal ionogram (sodium 135 - 145 mmol/l, potassium 3,5 - 4,5 mmol/l).~* Normal ferritin level (75 - 300 ng/ml)~* hs-CRP \<8 mg/l.~* Absence of arterial hypertension (systolic pressure \<140 mmHg and diastolic pressure \<90 mmHg).~* Non smoker or former smoker (quit smoking \>1 year).~* Alcohol consumption \<30 g/day.~Exclusion Criteria:~* Hyperthermia (T°\>38°c)~* Subject deprived of freedom by a court or administrative order~* Major protected by the law~* Subject who is in a period of relative exclusion due to his/her participation to another protocol or for whom the annual maximum amount of allowances of 3 811.23 € is reached.~* Subject who has been treated with anti-coagulants, anti-inflammatory drugs, b-blockers or insulin during the last month.~* Subject who cannot be subjected to muscle biopsy.~* Allergy to the anaesthetic~* Woman in age to procreate and not taking any oral or intra-uterine contraception

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Polyphenols (Type: EXPERIMENTAL): 9 weeks of supplementation with polyphenols(D56) and during the last week supplementation with polyphenols associated with a fructose load during the last 6 days (D63).
- placebo (Type: PLACEBO_COMPARATOR): 9 weeks of supplementation with placebo (D56) and during the last week supplementation with placebo associated with a fructose load during the last 6 days (D63).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of a Parenterally Administered H5N1 Influenza Vaccine in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy volunteers (as concluded from the medical history, physical examination, and clinical judgment) aged 19 to 50 years old~* Females using a reliable method of contraception (from 4 weeks prior to the first vaccination until 4 weeks after the second vaccination) and a negative urine pregnancy test will be required before administration of each dose of vaccine~* Signed informed consent~* Subjects able to understand and comply with the study protocol and complete the Adverse Event Form~* Subjects able to attend the scheduled visits~* Subjects with normal pre-screening values. If a subjects prescreening samples lie outside the reference values he/she will only be included in the study based upon the medical evaluation of the clinical investigator~Exclusion Criteria:~* Persons with a history of anaphylaxis or serious reactions to any vaccine~* Persons with known hypersensitivity to any of the vaccine components~* Persons who have had a temperature \>38oC during the previous 72 hours~* Persons who have had an acute respiratory infection during the last 7 days~* Women who are pregnant or breast-feeding~* Persons with chronic illness at any stage that could interfere with trial conduct or compliance~* Persons who have received blood products or immunoglobulins parenterally during the previous 3 months~* Persons who have been vaccinated with any vaccine during the 4 weeks preceding the first trial vaccination~* Persons with known or suspected immunosuppressive disease or who use systemic immunosuppressive drugs~* Persons taking immunostimulant therapy~* Persons involved in another clinical trial during the last month.~* Suspected non-compliance

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 30µg HA vaccine Intramuscularly administered
- 2 (Type: ACTIVE_COMPARATOR): 1.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
- 3 (Type: ACTIVE_COMPARATOR): 7.5µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered
- 4 (Type: ACTIVE_COMPARATOR): 30µg HA adjuvanted with 50µg 3rd generation ISCOM™ Intramuscularly administered

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rosiglitazone Effect on Mitochondria and Lipoatrophy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lipoatrophy~* Thymidine sparing ARV for at least 24 weeks~* Prior thymidine NRTIs for at least 12 months~Exclusion Criteria:~* Diabetes~* Heart failure~* Liver disease~* Hormonal therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rosigitazone arm (Type: ACTIVE_COMPARATOR): Rosiglitazone active 4 mg BID
- Placebo arm (Type: PLACEBO_COMPARATOR): Matching Placebo BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria :~* Participant is a healthy infant~* Participant has received one dose of monovalent hepatitis B vaccine prior to 1 month of age~Exclusion Criteria :~* Participant has received more than one dose of monovalent hepatitis B vaccine or hepatitis B based combination vaccine prior to study entry~* Participant has been vaccinated with any acellular pertussis or whole cell pertussis based combination vaccines, haemophilus influenzae type b conjugate, poliovirus, pneumococcal conjugate or pneumococcal polysaccharide, rotavirus, measles, mumps, rubella, or varicella vaccines or any combination of the above~* Participant has had an illness with fever within 24 hours of study enrollment~* Participant was vaccinated with any non-study vaccine (i.e. inactivated, conjugated or live virus vaccine within 30 days prior to enrollment, except for inactivated influenza vaccine, which is permitted 15 days or more prior to enrollment~* Participant or his/her mother has hepatitis B surface antigen (HBsAg) seropositivity (by medical history)~* Participant has a history of haemophilus influenzae type B, hepatitis B, diphtheria, tetanus, pertussis, poliomyelitis, rotavirus, or pneumococcal infection

- Gender: ALL
- Minimum Age: 46 Days
- Maximum Age: 89 Days
- Healthy Volunteers: t

Study Arms:
- V419 Lot A (Type: EXPERIMENTAL): V419 (Lot A) 0.5 mL intramuscular injection (IM) at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
- V419 Lot B (Type: EXPERIMENTAL): V419 (Lot B) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
- V419 Lot C (Type: EXPERIMENTAL): V419 (Lot C) 0.5 mL IM at 2, 4, and 6 months of age; Pentacel™ 0.5 mL IM at 15 month of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; and RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
- Control (Type: ACTIVE_COMPARATOR): Pentacel™ 0.5 mL IM at 2, 4, 6, and 15 months of age; Prevnar 13™ 0.5 mL IM at 2, 4, 6, and 15 months of age; RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age; and Recombivax HB vaccine 0.5 mL IM at 2 and 6 months of age

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Smoking adults aged ≥ 18 years intending to quit tobacco use who are prescribed Varenicline (Champix™) by their Physicians and those who are prescribed with Varenicline (Champix™) for the first time.~Exclusion Criteria:~* Subjects in whom varenicline (Champix™) may be taken in a manner that is not according to the approved local product document.~* Pregnant or lactating women, or women of childbearing potential not using an acceptable method of contraception~* Subjects with known hypersensitivity to varenicline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Open-label (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioenergetic Alterations After Exenatide Administration

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years of age~* BMI between 30 and 40 kg/m2~* Women with a negative pregnancy test at baseline, who are sterile, using contraceptives or in a committed relationship with someone who is sterile or using contraception~* Absence of weight change greater than 3 kg in the previous 6 months~Exclusion Criteria:~* Women who are pregnant or lactating~* Current or recent (6 months) enrollment in a commercial or self prescribed weight loss or exercise program~* Use of weight loss medication~* A history of metabolic disease i.e. renal, endocrine, hepatic or gastrointestinal disease that would impact the outcome of the study~* Presence of medical conditions that are known to affect energy expenditure (i.e. hyperthyroidism, rheumatoid arthritis, AIDS among others)~* History of hypoglycemia~* A history of psychiatric or eating disorder~* Abnormal EKG~* Previous history of pancreatitis~* Previous history of gastroparesis or GI motility disorder~* Use of medications that can affect GI motility~* History of organ transplantation~* Other comorbid conditions which may preclude the subject's ability to complete the study~* Use of a carbonic anhydrase inhibitor such as acetazolamide

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Exenatide (Type: EXPERIMENTAL): Exenatide. Dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks Each subject serves as their own control for outcome measures taken before and during drug treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* RMG Patients 18 years of age or older.~* Overdue for vaccination against influenza and/or not up to date on vaccination for pneumococcal vaccine per RMG EHR data~* No documented allergy to the vaccination in question.~Exclusion Criteria:~* Failure to meet inclusion criteria.~* Patients who have selected the Do not call option in the RMG EHR or have an allergy to the influenza and/or pneumococcal vaccination will be excluded from participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: E-portal message with IVR call (Type: ACTIVE_COMPARATOR): Patients identified as e-portal users will receive an e-portal message with IVR call
- Arm 2: E-portal message with no IVR call (Type: ACTIVE_COMPARATOR): Patients identified as e-portal users will receive an e-portal message only
- Arm 3: No e-portal message with IVR call (Type: ACTIVE_COMPARATOR): Patients identified as e-portal users will receive an IVR call only
- Arm 4: No E-portal message with no IVR call (Type: NO_INTERVENTION): Patients identified as e-portal users will receive neither an e-portal message nor an IVR call
- Arm 5: IVR call (Type: ACTIVE_COMPARATOR): Patients identified as non e-portal users will receive an IVR call only
- Arm 6: No IVR call (Type: NO_INTERVENTION): Patients identified as non e-portal users will not receive any outreach

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Decitabine Given to Adults With Advanced-Stage Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Must sign an Institutional Review Board (IRB) -approved informed consent form.~2. Must be 18 years of age or older.~3. Must have a diagnosis for MDS fitting any of the recognized French-American-British (FAB) classifications and International Prognostic Scoring System (IPSS) greater than or equal to 0.5 as determined by Complete Blood Count (CBC), bone marrow assessment, and cytogenetics within 28 days of receiving study drug. If FAB classification is Refractory anemia (RA) or Refractory anemia with ringed sideroblasts (RARS), then must be red cell transfusion dependent, defined as needing red cells more frequently than once every 4 weeks.~4. If receiving erythropoietin(Procrit), must have been on a stable dose for at least 8 weeks before first dose of study drug.~5. If receiving darbepoetin(Aranesp), must have been on a stable dose for at least 12 weeks before first dose of study drug.~Exclusion Criteria:~1. Must not have a diagnosis of Acute Myeloid Leukemia (AML) or other progressive malignant disease.~2. Must not have received any investigational agent within the 30 days preceding the first dose of study drug.~3. Must not have uncontrolled cardiac disease or uncontrolled congestive heart failure.~4. Must not have an active viral or bacterial infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* HCV RNA ≥ 10\^4 IU/mL at screening~* Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy~* Any HCV genotype (1, 2, 3, 4, 5, 6 or indeterminate)~* HCV treatment-naive or treatment-experienced~* Liver imaging within 6 months of Day 1 is required in cirrhotic patients only to exclude hepatocellular carcinoma (HCC)~Key Exclusion Criteria:~* Current or prior history of clinically-significant illness (other than HCV), gastrointestinal disorder, clinical hepatic decompensation, or post-operative condition that could interfere with the absorption of the study drug~* Pregnant or nursing female or male with pregnant female partner~* Chronic liver disease of a non HCV etiology~* Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL FDC for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Outcomes of Intrathecal Analgesia in Colorectal Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All adult colorectal patients from October 2012 through December 2013 in which patients received single-injection IA as part of a multimodal analgesic strategy for ERP.~* Undergoing an elective colorectal operation (minimally invasive or open)~Exclusion Criteria:~* Patients aged \< 18 years~* American Society of Anesthesiologists (ASA) 5 and 6 classification~* pregnancy~* failure to provide research authorization.~* emergent operations

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Opioid Only Intrathecal (Type: None): None
- Opioid + Local Anesthetic Intrathecal (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Health-E You: Reducing Unintended Pregnancies Among Hispanic Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Female 14-18 years of age Hispanic/Latina English or Spanish-speaker Has had sexual intercourse~Exclusion Criteria:~Currently pregnant Currently using an intrauterine device or implant contraceptive method Male Under 14 or over 19 years of age Not sexually active Non-Hispanic / Latina

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Health-E You App Participants (Type: EXPERIMENTAL): None
- Control Group (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete